Reuters logo
BRIEF-Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018
August 30, 2017 / 10:51 AM / 21 days ago

BRIEF-Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018

Aug 30 (Reuters) - Incyte Corp

* Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018

* Eli lilly and Co - ‍resubmission package will include new safety and efficacy data​

* Eli Lilly and Co - Phase 3 program for psoriatic arthritis is expected to begin in 2018

* Eli Lilly says ‍companies anticipate FDA will classify application as a Class II resubmission, which will start a new six-month review cycle​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below